Frontiers in Oncology · 2015 · 17 citations · 23 references
MedicineOncologyRadiation OncologyMedical OncologyThoracic OncologyTreatment PlanningLung CancerMalignant NeoplasmsRadiation TherapyRadiation Treatment PlanningToxicity ManagementActuarial Survival AnalysisLocal Control AssessmentLocalizing Recurrent DiseaseNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentStereotactic Ablative RadiotherapyStereotactic Body Radiotherapy DosimetryStereotactic Body Radiotherapy Toxicity
INTRODUCTION: Stereotactic ablative body radiotherapy (SABR) provides a superior non-small cell lung cancer (NSCLC) treatment option when compared to conventional radiotherapy for patients deemed inoperable or refusing surgery. This study retrospectively analyzed the rates of tumor control and toxicity following SABR treatment (Cyberknife system) of primary early-stage NSCLC in a community setting. METHODS: One hundred patients were treated between 2007 and 2011. Patients with T3-4 or N1-3 disease, metastasis, recurrent local disease, or a non-lung primary were excluded from analysis. All patients had biopsy proven disease. Staging included CT or fluorodeoxyglucose-positron emission tomography scan. Median dose was 54 Gy (45-60); 18 Gy (10-20) per fraction. Median planned target volume expansion was 8 mm (2-10). Median BED was 151.2. Tumors were tracked via Synchrony, X-Sight Lung, or X-Sight Spine. Patients were evaluated for local control, overall survival (OS), and toxicity. All local failures were determined by evaluating post treatment PET/CT. RESULTS: With a median follow up of 27.5 months, the 1-, 2-, and 3-year local control rates were 100, 93.55, and 84.33%, respectively. Median survival was 2.29 years; actuarial 3-year survival was 37.20%. Grade-3 toxicity was observed in 2% of patients (pneumonia within 2 months of treatment, n = 1; chronic pneumonitis requiring hospital admission, n = 1). No patients demonstrated toxicity above Grade-3. Multivariate analysis did not show T-stage as an independent predictor of OS, though it did trend toward significance. CONCLUSION: In a community-center setting, definitive treatment of NSCLC with SABR for non-surgical candidates and those who choose to forego surgery result in excellent and comparable rates of local control and toxicity compared to published series from large academic centers.
23
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Robert Timmerman · JAMA · 2010 · 2.5K citations · Full text
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
Nicola Aceto, Aditya Bardia, David T. Miyamoto et al. · Cell · 2014 · 2.5K citations · Full text
Medicine, Cancer Biology, Oncology +12
Robert Timmerman, Ronald C. McGarry, Constantin T. Yiannoutsos et al. · Journal of Clinical Oncology · 2006 · 1.5K citations · Full text
Medicine, Radiation Oncology, Clinical Radiation Oncology +16
Hiroshi Onishi, Hiroki Shirato, Yasushi Nagata et al. · Journal of Thoracic Oncology · 2007 · 976 citations · Full text
Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma
Hiroshi Onishi, Tsutomu Araki, Hiroki Shirato et al. · Cancer · 2004 · 906 citations · Full text